PSMA-Targeting Radiopharmaceuticals for Prostate Cancer Therapy: Recent Developments and Future Perspectives

SIMPLE SUMMARY: One of the most frequently diagnosed cancer in men is adenocarcinoma of the prostate. Once the disease is metastatic, only very limited treatment options are available, resulting in a very short median survival time of 13 months; however, this reality is gradually changing due to the...

Descripción completa

Detalles Bibliográficos
Autores principales: El Fakiri, Mohamed, Geis, Nicolas M., Ayada, Nawal, Eder, Matthias, Eder, Ann-Christin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8393521/
https://www.ncbi.nlm.nih.gov/pubmed/34439121
http://dx.doi.org/10.3390/cancers13163967

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8393521/
https://www.ncbi.nlm.nih.gov/pubmed/34439121
http://dx.doi.org/10.3390/cancers13163967

Ejemplares similares